相关实验视频
Updated: Jun 21, 2025

04:49
Technique for Intranasal Administration of α-Synuclein Aggregates
Published on: November 8, 2024
433
多系统性缩中的行为变化的病理生物学:最新情况
1Institute of Clinical Neurobiology, Alberichgasse 5/13, 1150 Vienna, Austria.
International journal of molecular sciences
|July 13, 2024
概括
焦虑和冷漠等行为障碍在多系统缩 (MSA) 中很常见. 了解它们的机制对于开发这种罕见的神经退行性疾病的生物标志物和治疗方法至关重要.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 精神病学是一个精神病学.
背景情况:
- 在多重系统缩 (MSA) 中,行为障碍很普遍,影响30%-70%的患者.
- 这些包括焦虑,冷漠,注意力缺陷,强迫行为和REM睡眠行为障碍 (RBD).
- 这些症状是早期的,普遍的,并且可能会影响这种同核蛋白病变的疾病进展.
研究的目的:
- 探索不太了解的病理生理学和生化机制,这些机制是MSA行为障碍的基础.
- 调查MSA中特定行为症状的神经成像相关性.
- 强调需要进一步研究这些使人衰弱的并发病症的发病性.
主要方法:
- 审查现有的神经成像研究,将特定的行为变化与大脑电路功能障碍联系起来.
- 检查在MSA中α-synuclein病理和焦虑之间提出的关联.
- 关于REM睡眠行为障碍 (RBD) 和单氨基缺陷之间的关系的分析.
主要成果:
- 神经成像在焦虑中涉及皮质 - 边缘变化,在冷漠 / 抑郁中涉及前额叶 - 下皮质功能障碍,在强迫行为中涉及基底腺 / 轨道 - 前额损伤.
- 焦虑与杏仁体α-synuclein病理有关;RBD与条状单氨基酶缺陷有关.
- 其他行为障碍的机制及其与非运动功能障碍的联系在很大程度上是未知的.
结论:
- 行为障碍是显著的,多系统缩 (MSA) 的早期特征,具有复杂的潜在机制.
- 目前对病变发生的理解是有限的,特别是在生化和功能方面.
- 进一步的神经成像和生物化学研究对于开发诊断生物标志物和有效治疗MSA相关行为症状至关重要.
更多相关视频
14:45Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
5.9K
10:03Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
Published on: August 16, 2020
10.6K
相关概念视频
Parkinson's Disease: Overview
522
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
522
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461